Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Interest Expenses (2016 - 2025)

Historic Interest Expenses for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $3.0 million.

  • United Therapeutics' Interest Expenses fell 7029.7% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year decrease of 5149.7%. This contributed to the annual value of $42.9 million for FY2024, which is 2765.6% down from last year.
  • As of Q3 2025, United Therapeutics' Interest Expenses stood at $3.0 million, which was down 7029.7% from $7.3 million recorded in Q2 2025.
  • United Therapeutics' 5-year Interest Expenses high stood at $15.6 million for Q3 2023, and its period low was $3.0 million during Q3 2025.
  • For the 5-year period, United Therapeutics' Interest Expenses averaged around $8.9 million, with its median value being $7.9 million (2024).
  • Per our database at Business Quant, United Therapeutics' Interest Expenses surged by 19361.7% in 2023 and then tumbled by 7029.7% in 2025.
  • Over the past 5 years, United Therapeutics' Interest Expenses (Quarter) stood at $4.7 million in 2021, then skyrocketed by 161.7% to $12.3 million in 2022, then rose by 22.76% to $15.1 million in 2023, then plummeted by 47.68% to $7.9 million in 2024, then tumbled by 62.03% to $3.0 million in 2025.
  • Its Interest Expenses stands at $3.0 million for Q3 2025, versus $7.3 million for Q2 2025 and $6.1 million for Q1 2025.